INDIVIDUAL ARTICLE: Efficacy of a Prebiotic Skincare Regimen on Improving Mild Atopic Dermatitis and Severe Xerosis in Diverse Ethnically Patients
March 2024 | Volume 23 | Issue 3 | SF395747s12 | Copyright © March 2024
Published online March 1, 2024
Hawasatu Dumbuya PhDa, Katharine Podimatis MDa, Delphine Kerob MDb, Zoe Diana Draelos MDc
aLa Roche-Posay Laboratoire Dermatologique, L'Oreal USA, New York, NY
bLa Roche-Posay Laboratoire Dermatologique, L'Oreal, Levallois-Perret, France
cDermatology Consulting Services, PLLC, High Point, NC
Abstract
Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease associated with a significant patient burden on quality of life. Given skin barrier including skin microbiome changes are linked to AD pathogenesis, prebiotic emollients are shown to improve disease symptoms and maintain skin barrier integrity, normalizing skin microbiota. In this study, we evaluated the efficacy and safety of a prebiotic skincare routine in improving AD and xerosis, and ultimately quality-of-life in ethnically diverse patients. A total of 140 subjects from different racial/ethnic backgrounds, aged 3-80 years old with skin phototypes I-VI, and presenting with mild-AD or severe xerosis completed study. Expert grading, instrumentation, self-assessment questionnaires, plus clinical imaging demonstrated that a prebiotic cleanser and moisturizer routine significantly reduced skin conditions severity, strengthened skin barrier properties in both lesional and normal skin, and improved patients' quality-of-life while providing itch relief as soon as 4 weeks. The results of this research indicate that a prebiotic cleanser and moisturizer regimen offers benefits for diverse patients' daily skincare routine by effectively managing AD and xerosis severity and symptoms, normalizing skin microbiota, plus preserving skin barrier integrity to prevent long-term sequelae.
J Drugs Dermatol. 2024;23:3(Suppl 2):s12-s22.
INTRODUCTION
Atopic dermatitis (AD) is a common and heterogeneous chronic relapsing inflammatory skin disease, characterized with eczematous and pruritic lesions.1 Affecting both children and adults, it is associated with a significant burden on patients' quality of life and several comorbidities, such as skin pain, sleep disturbance, and depression.2,3 AD epidemiology studies report a higher incidence and prevalence among patients with skin of color (SOC).4-9 In the US, African American children are 1.7 times likely to develop AD than their European American counterparts, and 3 times more likely to be diagnosed with disease after a dermatology visit.10,11 SOC individuals also have increased cost of care and prolonged length of stay associated with their AD.12 These nuances between racial/ethnic groups may require different approaches to AD treatment to effectively manage symptoms and prevent long-term sequelae.
AD pathophysiology is multifactorial and involves gene predisposition, skin barrier dysfunction, environmental triggers, immune dysregulation, and microbial dysbiosis.1,13-17 Rising evidence demonstrate skin microbiome playing an essential role in AD pathogenesis.16-18
